Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developments in therapeutics for pulmonary arterial hypertension.

Minerva cardioangiologica - 1 Jun 2002

Wilkins M R, Møller G M O, Ren X, Wharton J

Abstract excerpt

For many years, the management of pulmonary hypertension has been frustrated by an inadequate understanding of its pathology and limited therapeutic options, but this is changing rapidly. Recently, novel insight into the pathogenesis of primary pulmonary hypertension (PPH) has been provided by the demonstration of mutations in BMPR2 and ALK-1 genes in a significant number of patients with the condition. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Endothelins
Share to Hypertension, Pulmonary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphodiesterase Inhibitors

Share to Purines

Share to Receptors, Transforming Growth Factor beta

Share to Sulfones

Share to Vasodilator Agents

Source

Identifiers

PMID: 12107399

Genes

ALK
BMPR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developments in therapeutics for pulmonary arterial hypertension.PMID 12107399Read ↗

Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.Semantic proximity Read ↗

An emerging class of new therapeutics targeting TGF , Activin, and BMP ligands in pulmonary arterial hypertensionSemantic proximity Read ↗

Pulmonary hypertension: advances in pathogenesis and treatment.Semantic proximity Read ↗

Recent advances in pulmonary arterial hypertensionSemantic proximity Read ↗

Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities.Semantic proximity Read ↗

New insights into the pathogenesis and treatment of primary pulmonary hypertension.Semantic proximity Read ↗

Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies.Semantic proximity Read ↗

Anticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial HypertensionSemantic proximity Read ↗

Management of Pulmonary Arterial Hypertension. Current Strategies and Future ProspectsSemantic proximity Read ↗

[Pulmonary (Arterial) Hypertension].Semantic proximity Read ↗

Significance of BMPR2 mutations in pulmonary arterial hypertension.Semantic proximity Read ↗

Novel Advances in Modifying BMPR2 Signaling in PAHSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.